Human medicines European public assessment report (EPAR): Brintellix, vortioxetine, Date of authorisation: 18/12/2013, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Brintellix, vortioxetine, Date of authorisation: 18/12/2013, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Wegovy, semaglutide, Date of authorisation: 06/01/2022, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Wegovy, semaglutide, Date of authorisation: 06/01/2022, Revision: 13, Status: Authorised

HMA/EMA multi-stakeholder workshop on artificial intelligence (AI), Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 November 2025, 13:00 (CET) to 21 November 2025, 12:50 (CET)

HMA/EMA multi-stakeholder workshop on artificial intelligence (AI), Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 November 2025, 13:00 (CET) to 21 November 2025, 12:50 (CET)

Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation: 13/11/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation: 13/11/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Date of authorisation: 03/04/2020, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Date of authorisation: 03/04/2020, Revision: 16, Status: Authorised

Deadlines for submission of applications for orphan medicinal product designation to the EMA and corresponding COMP timetable for valid applications 2026-2027

Deadlines for submission of applications for orphan medicinal product designation to the EMA and corresponding COMP timetable for valid applications 2026-2027

Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 4, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.